CA125, Galectin-3 and FGF-23 are interrelated in heart failure with reduced ejection fraction.
EJIFCC
; 34(2): 103-109, 2023 Jul.
Article
en En
| MEDLINE
| ID: mdl-37455845
ABSTRACT
Background:
Carbohydrate Antigen 125 (CA125) is the most widely used biomarker in ovarian cancer screening. In patients with heart failure (HF), increased levels of CA125 have been observed and related to disease severity. Our objective was to determine the association of CA125 levels with two biomarkers of adverse remodeling in HF patients with reduced ejection fraction (HFrEF).Methods:
CA125 circulating levels were determined with an electrochemiluminscent immunoassay. Concentrations of B-type natriuretic peptide (BNP), N-terminal proBNP (Nt-proBNP), Galectin-3 and Fibroblast Growth Factor 23 (FGF23) were also measured by immunoassays.Results:
CA125 levels were increased in HFrEF, were associated to disease severity according NYHA classes. Median CA125 concentration was also significantly related to cardiovascular mortality. CA125 concentrations were positively and significantly associated to Galectin-3 and FGF23.Conclusions:
Concentrations of CA125 are increased in patients with HFrEF, associated to disease severity and adverse cardiovascular outcomes. CA125 levels are also correlated to Galectin-3 and FGF-23, two biomarkers related to fibrosis and cardiovascular remodeling.
Texto completo:
1
Bases de datos:
MEDLINE
Idioma:
En
Revista:
EJIFCC
Año:
2023
Tipo del documento:
Article
País de afiliación:
Bélgica